Accelerate Diagnostics

Accelerate Diagnostics Tax Expense

Delisted

The Income Tax Expense of Accelerate Diagnostics (AXDX) as of Nov 12, 2026 is -66,000.00 USD. In the previous year, Income Tax Expense was 850,000.00 USD — a change of -107.76% (lower).

Tax Expense

-66,000.00USD

YoY

-107.76%

Last updated:

Income Tax Expense of Accelerate Diagnostics is 2024 -66,000.00 USD. Income Tax Expense of Accelerate Diagnostics was 2023 850,000.00 USD. It decreases by -107.76% lower compared to the previous year.

The Accelerate Diagnostics Tax Expense history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tax Expense
Date
Tax Expense
Jan 1, 2017
-651,000.00 USD
Jan 1, 2018
211,000.00 USD
Jan 1, 2019
-111,000.00 USD
Jan 1, 2020
5,000.00 USD
Jan 1, 2021
45,000.00 USD
Jan 1, 2022
-77,000.00 USD
Jan 1, 2023
850,000.00 USD
Jan 1, 2024
-66,000.00 USD
The Accelerate Diagnostics Tax Expense history
YEARTax ExpenseYoY
-66,000.00USD-107.76%
850,000.00USD-1,203.90%
-77,000.00USD-271.11%
45,000.00USD+800.00%
5,000.00USD-104.50%
-111,000.00USD-152.61%
211,000.00USD-132.41%
-651,000.00USD-343.82%
267,000.00USD+260.81%
74,000.00USD-114.04%
-527,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Accelerate Diagnostics Stock analysis

What does Accelerate Diagnostics do? Accelerate Diagnostics, Inc. generates revenue through its Accelerate Pheno system, an in vitro diagnostic platform that combines genotypic pathogen identification with phenotypic antibiotic susceptibility testing. The company sells the Accelerate Pheno system, including the fixed instrument and single-use test kits, to healthcare facilities for rapid diagnosis of serious infections. The Accelerate PhenoTest BC Kit specifically targets bacteremia and fungemia cases, providing ID and AST results directly from patient samples. Healthcare providers, particularly those treating life-threatening infections with high mortality risks, purchase these solutions to improve patient outcomes and reduce healthcare costs. The Accelerate Pheno system's walk-away automation feature reduces manual labor in laboratories, appealing to hospitals and clinical labs seeking efficiency. The company's focus on rapid diagnosis of serious infections aligns with healthcare institutions' needs for faster treatment decisions. By offering direct pathogen identification followed by targeted antibiotic testing, the system helps clinicians choose effective treatments more quickly, addressing high morbidity and mortality risks associated with bloodstream infections. Accelerate Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Accelerate Diagnostics stock

Income Tax Expense of Accelerate Diagnostics is -66,000.00 USD in 2024.

Income Tax Expense of Accelerate Diagnostics changed from 850,000.00 USD to -66,000.00 USD, representing a -107.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Income Tax Expense Accelerate Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Tax expense represents the total income taxes owed. It reflects the company's tax obligations and effective tax rate.

Income Tax Expense's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Income Tax Expense's Accelerate Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Accelerate Diagnostics

All Key Metrics — Accelerate Diagnostics